Preclinical pharmacology of fluoxetine, a serotonergic drug for weight loss
- PMID: 1728830
- DOI: 10.1093/ajcn/55.1.177s
Preclinical pharmacology of fluoxetine, a serotonergic drug for weight loss
Abstract
Fluoxetine selectively inhibits serotonin uptake in vitro and in vivo and thus enhances serotonergic function, leading to a decrease in food intake beginning with the first dose and a decrease in body weight or in weight gain after multiple doses of fluoxetine. Fluoxetine and other drugs that increase serotonergic function decrease food intake with characteristics that make them attractive for use in weight reduction. In rats, for instance, fluoxetine and other serotonergic drugs suppress stress-induced eating, suppress carbohydrate consumption selectively, and suppress insulin-induced hyperphagia. Fluoxetine and other serotonergic drugs do not cause amphetamine-like behavioral stimulation in animals and have no known abuse or addiction liability. In obese yellow mice and in normal mice, as in rats, fluoxetine causes a sustained decrease in food intake and body weight. The pharmacologic effects of fluoxetine in animals suggest its potential use in weight-reduction programs in obese humans.
Similar articles
-
Appraisal of the clinical value of serotoninergic drugs.Am J Clin Nutr. 1992 Jan;55(1 Suppl):189S-192S. doi: 10.1093/ajcn/55.1.189s. Am J Clin Nutr. 1992. PMID: 1728833 Review.
-
Progress report on the anorectic effects of dexfenfluramine, fluoxetine and sertraline.Int J Obes Relat Metab Disord. 1992 Dec;16 Suppl 3:S43-50. Int J Obes Relat Metab Disord. 1992. PMID: 1338321 Review.
-
Hyperphagia and weight loss during fluoxetine treatment.Ann Pharmacother. 1994 Dec;28(12):1350-2. doi: 10.1177/106002809402801205. Ann Pharmacother. 1994. PMID: 7696724
-
Sertraline, a serotonin-uptake inhibitor, reduces food intake and body weight in lean rats and genetically obese mice.Am J Clin Nutr. 1992 Jan;55(1 Suppl):185S-189S. doi: 10.1093/ajcn/55.1.185s. Am J Clin Nutr. 1992. PMID: 1728832
-
Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers.Neuropsychopharmacology. 1993 Nov;9(3):201-10. doi: 10.1038/npp.1993.56. Neuropsychopharmacology. 1993. PMID: 8280344
Cited by
-
Differential Rearing Alters Forced Swim Test Behavior, Fluoxetine Efficacy, and Post-Test Weight Gain in Male Rats.PLoS One. 2015 Jul 8;10(7):e0131709. doi: 10.1371/journal.pone.0131709. eCollection 2015. PLoS One. 2015. PMID: 26154768 Free PMC article.
-
Xiaoyaosan Improves Depressive-Like Behaviors in Mice through Regulating Apelin-APJ System in Hypothalamus.Molecules. 2018 May 3;23(5):1073. doi: 10.3390/molecules23051073. Molecules. 2018. PMID: 29751542 Free PMC article.
-
Psychotropic drugs in the treatment of obesity: what promise?CNS Drugs. 2004;18(10):629-51. doi: 10.2165/00023210-200418100-00002. CNS Drugs. 2004. PMID: 15270593 Review.
-
Vilazodone, a Novel SSRI Antidepressant with 5-HT1A Partial Agonist Properties: Diminished Potentiation of Chronic Oral Methylphenidate-Induced Dynorphin Expression in the Striatum in Adolescent Male Rats.Mol Neurobiol. 2025 Apr;62(4):4520-4532. doi: 10.1007/s12035-024-04569-8. Epub 2024 Oct 28. Mol Neurobiol. 2025. PMID: 39466575 Free PMC article.
-
Increased response to a 5-HT challenge after discontinuation of chronic serotonin uptake inhibition in the adult and adolescent rat brain.PLoS One. 2014 Jun 17;9(6):e99873. doi: 10.1371/journal.pone.0099873. eCollection 2014. PLoS One. 2014. PMID: 24937739 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical